Memphasys Limited (MEM.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 4.41 Million AUD | -24.53% |
| 2023 | 6.37 Million AUD | 14.56% |
| 2022 | 5.56 Million AUD | 3.82% |
| 2021 | 5.35 Million AUD | 414.72% |
| 2020 | 1.04 Million AUD | 15336.69% |
| 2019 | 6743.00 AUD | -98.6% |
| 2018 | 482.03 Thousand AUD | -92.85% |
| 2017 | 6.73 Million AUD | 37.92% |
| 2016 | 4.88 Million AUD | -9.03% |
| 2015 | 5.37 Million AUD | -20.03% |
| 2014 | 6.71 Million AUD | 228.02% |
| 2013 | 2.04 Million AUD | 91.64% |
| 2012 | 1.06 Million AUD | 183.19% |
| 2011 | 377.28 Thousand AUD | 277.29% |
| 2010 | 100 Thousand AUD | -75.11% |
| 2009 | 401.8 Thousand AUD | -70.39% |
| 2008 | 1.35 Million AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 FY | 4.75 Million AUD | -25.31% |
| 2024 Q2 | 5.54 Million AUD | 0.0% |
| 2024 Q4 | 4.41 Million AUD | 0.0% |
| 2023 Q2 | 5.46 Million AUD | 0.0% |
| 2023 Q4 | 6.37 Million AUD | 0.0% |
| 2023 FY | 6.37 Million AUD | 14.56% |
| 2022 Q2 | 5.59 Million AUD | 0.0% |
| 2022 Q4 | 5.56 Million AUD | 0.0% |
| 2022 FY | 5.56 Million AUD | 3.82% |
| 2021 FY | 5.35 Million AUD | 414.72% |
| 2021 Q4 | 5.35 Million AUD | 0.0% |
| 2021 Q2 | 983.99 Thousand AUD | 0.0% |
| 2020 Q2 | 1.08 Million AUD | 0.0% |
| 2020 FY | 1.04 Million AUD | 15336.69% |
| 2020 Q4 | 1.04 Million AUD | 0.0% |
| 2019 FY | 6743.00 AUD | -98.6% |
| 2019 Q4 | 6743.00 AUD | 0.0% |
| 2019 Q2 | 1.12 Million AUD | 0.0% |
| 2018 FY | 482.03 Thousand AUD | -92.85% |
| 2018 Q4 | 482.03 Thousand AUD | 0.0% |
| 2018 Q2 | 746.77 Thousand AUD | 0.0% |
| 2017 Q4 | 6.76 Million AUD | 0.0% |
| 2017 FY | 6.73 Million AUD | 37.92% |
| 2017 Q2 | 5.73 Million AUD | 0.0% |
| 2016 Q2 | 5.89 Million AUD | 0.0% |
| 2016 FY | 4.88 Million AUD | -9.03% |
| 2016 Q4 | 4.88 Million AUD | 0.0% |
| 2015 Q4 | 5.37 Million AUD | 0.0% |
| 2015 Q2 | 4.39 Million AUD | 0.0% |
| 2015 FY | 5.37 Million AUD | -20.03% |
| 2014 Q2 | 2.22 Million AUD | 0.0% |
| 2014 FY | 6.71 Million AUD | 228.02% |
| 2014 Q4 | 6.71 Million AUD | 0.0% |
| 2014 Q3 | - AUD | -100.0% |
| 2014 Q1 | - AUD | -100.0% |
| 2013 Q2 | - AUD | 0.0% |
| 2013 Q1 | - AUD | -100.0% |
| 2013 Q4 | 2.04 Million AUD | 0.0% |
| 2013 FY | 2.04 Million AUD | 91.64% |
| 2013 Q3 | - AUD | 0.0% |
| 2012 FY | 1.06 Million AUD | 183.19% |
| 2012 Q4 | 1.06 Million AUD | 0.0% |
| 2011 Q4 | 377.28 Thousand AUD | 0.0% |
| 2011 FY | 377.28 Thousand AUD | 277.29% |
| 2010 FY | 100 Thousand AUD | -75.11% |
| 2010 Q4 | 100 Thousand AUD | 0.0% |
| 2009 Q4 | 401.8 Thousand AUD | 0.0% |
| 2009 FY | 401.8 Thousand AUD | -70.39% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | 1.35 Million AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 123.85 Thousand AUD | -3463.149% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Zelira Therapeutics Limited | 5.65 Million AUD | 21.939% |
| Biome Australia Limited | 1.3 Million AUD | -237.988% |
| Patrys Limited | - AUD | -Infinity% |
| Orthocell Limited | 689.69 Thousand AUD | -539.875% |
| Imugene Limited | 1.54 Million AUD | -185.287% |
| Noxopharm Limited | - AUD | -Infinity% |
| PYC Therapeutics Limited | 1.11 Million AUD | -296.586% |
| Chimeric Therapeutics Limited | - AUD | -Infinity% |
| Prescient Therapeutics Limited | 330.48 Thousand AUD | -1235.359% |
| Proteomics International Laboratories Limited | 316.39 Thousand AUD | -1294.831% |
| Cynata Therapeutics Limited | - AUD | -Infinity% |
| CSL Limited | 18.24 Billion AUD | 99.976% |
| Arovella Therapeutics Limited | - AUD | -Infinity% |
| Bio-Gene Technology Limited | - AUD | -Infinity% |
| Clinuvel Pharmaceuticals Limited | 879.78 Thousand AUD | -401.62% |
| Starpharma Holdings Limited | 3.52 Million AUD | -25.09% |
| Nanollose Limited | 42.53 Thousand AUD | -10276.614% |
| Invex Therapeutics Ltd | - AUD | -Infinity% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 1.56 Million AUD | -182.584% |
| Botanix Pharmaceuticals Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 421.96 Thousand AUD | -945.855% |
| Race Oncology Limited | - AUD | -Infinity% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 17.44 Million AUD | 74.702% |
| Dimerix Limited | 149.68 Thousand AUD | -2848.347% |
| PharmAust Limited | - AUD | -Infinity% |
| Immutep Limited | 1.22 Million AUD | -259.301% |
| Clarity Pharmaceuticals Ltd | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 159.04 Thousand AUD | -2674.796% |
| BTC Health Limited | - AUD | -Infinity% |
| Acrux Limited | 1.48 Million AUD | -196.784% |
| Neuren Pharmaceuticals Limited | - AUD | -Infinity% |
| Biotron Limited | 7130.00 AUD | -61795.849% |
| Tissue Repair Ltd | - AUD | -Infinity% |
| AdAlta Limited | 2.49 Million AUD | -76.912% |
| Radiopharm Theranostics Limited | - AUD | -Infinity% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 23.59 Thousand AUD | -18606.231% |
| Paradigm Biopharmaceuticals Limited | 239.33 Thousand AUD | -1743.97% |
| Recce Pharmaceuticals Ltd | 811.19 Thousand AUD | -444.037% |
| Avecho Biotechnology Limited | 175.15 Thousand AUD | -2419.64% |
| Actinogen Medical Limited | 319.06 Thousand AUD | -1283.141% |
| Immuron Limited | 173.49 Thousand AUD | -2443.66% |
| Argenica Therapeutics Limited | - AUD | -Infinity% |